ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relativ e effect CI) Anticipated absolute effects Risk with medical therapy Risk difference with CABG (95% CI) Quality of life - SF-12 (Mental Component) MODERATEa due to risk of bias The mean quality of life SF-12(mental component) at 12 months in the control groups was The mean quality of life SF-12 (mental component) at 12 months in the intervention groups was All-cause hospitalisations 1212 MODERATEb due to imprecision (from 34 fewer to 141 fewer) Subsequent procedures - CABG 1212 MODERATEa due to risk of bias Peto Odds Ratio (from 138 fewer to 153 fewer) Subsequent procedures - PCI 1212 LOWa,b due to risk of bias, imprecision (from 35 fewer to 8 more) NYHA class I 1212 LOWb,c due to imprecision, indirectness (from 21 more to 140 more) LOWa,b due to risk of (from 16 fewer to 47 more) Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relativ e effect CI) Anticipated absolute effects Risk with medical therapy Risk difference with CABG (95% CI) bias, imprecision (a) Downgraded by 1 increment if majority of the evidence was rated high risk of bias, downgraded by 2 increments if majority of the evidence was rated very high risk of bias. (b) Downgraded by 1 increment if the confidence interval crossed one MID, downgraded by 2 increments if the confidence interval crossed both MIDs. (c) Downgraded by 1 increment due to indirectness of the outcome (protocol outcome improvement in NYHA class; extracted outcome no. in NYHA class I). 